October 2024
NHS England to Roll Out Eli Lilly’s Obesity Drug Mounjaro in Phased Approach
NHS England, Eli Lilly, Mounjaro, Obesity Drug, Phased Rollout, Weight Loss, Tirzepatide
Pfizer Announces Layoffs in Ireland Amid Global Cost-Cutting Efforts
Pfizer layoffs, Ireland, cost-cutting, pharmaceutical industry, job cuts
Travere Therapeutics Pauses Phase 3 HARMONY Study Due to Manufacturing Scale-Up Challenges
Travere Therapeutics, Phase 3 HARMONY Study, Pegtibatinase, Classical Homocystinuria, Manufacturing Scale-Up Issue
CMS Prepares for Second Round of Medicare Drug Price Negotiation Program
Medicare Drug Price Negotiation Program, CMS, drug price negotiations, Inflation Reduction Act, Part D drugs, maximum fair prices (MFPs)
Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees
Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction
Senators Wyden and Brown Call for FTC Investigation into PBM “Co-Manufacturing” Practices
PBM reforms, FTC investigation, co-manufacturing, pharmacy benefit managers, drug costs, competition, healthcare industry
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Zephyrm Seeks Hong Kong IPO to Fund Phase III Cell Therapy Trials
Zephyrm, IPO, cell therapy, Phase III trials, Hong Kong listing
Eli Lilly Invests $4.5 Billion in Groundbreaking Indiana Manufacturing and R&D Facility
Eli Lilly, pharmaceutical manufacturing, R&D, Indiana, Lilly Medicine Foundry, clinical trials, drug development
Johnson & Johnson Invests $2 Billion in New North Carolina Biologics Facility
Johnson & Johnson, North Carolina, Biologics Facility, Pharmaceutical Manufacturing, Investment